Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.
Talk to the deal team
Related deals
Xeros Technology Group has completed a placing, subscription and retail offer
Xeros Technology Group plc has raised funds to drive forward its commercialization strategy.
Learn morePCI Pal has completed an equity raise
PCI Pal has completed a fundraising. Funds will be allocated towards several key areas, with a significant portion directed towards supporting its continued expansion in the US, focusing on marketing efforts, product marketing and enhancing engagement with key partners.
Learn moreNavitas Petroleum has issued stocks
Navitas Petroleum has completed a fundraising to refinance and develop the company.
Learn more